FDA approves Zoryve (roflumilast) cream 0.3% for treatment of psoriasis in children ages 6 to 11- Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. announced the FDA has approved the supplemental new drug application (sNDA) to expand the indication of Zoryve (roflumilast) cream 0.3% for the topical treatment of… read more.
